Chordate Medical Holding
8.6
SEK
-3.37 %
CMH
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
1 following
-3.37%
-4.23%
-51.14%
-75.98%
-71.24%
-84.9%
-97.52%
-95.91%
-99.55%
Chordate Medical Holding is a medical technology company that has developed, patented and CE-marked a nerve-modulating treatment technique for chronic migraine and chronic nasal congestion (rhinitis), Kinetic Oscillation Stimulation (KOS). The company sells its products to treating clinics in selected European markets, Israel and Saudi Arabia, with the aim of increasing its presence in the global market.
Read moreMarket cap
9.53M SEK
Turnover
5.65K SEK
Revenue
980K
EBIT %
-3,017.35 %
P/E
-
Dividend yield-%
-
Financial calendar
28.2
2025
Annual report '24
21.5
2025
General meeting '24
23.5
2025
Interim report Q1'25
ShowingAll content types
Chordate decides on a preferential issue of units of approximately SEK 22.2 million consisting of ordinary shares and preference shares with a conditional share dividend upon sale of the business
BioStock: Chordate Medical's CEO looks ahead to 2025 - "The exit process is our primary focus"
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools